OBJECTIVES: The microRNA 142 (miR-142) is expressed at high levels in mature hematopoietic cells and has a crucial role during T-lymphocyte development. Its role in leukemogenesis is unclear. PATIENTS AND METHODS: Expression of miR-142 was analyzed in acute myeloid and lymphoblastic leukemia cells (de novo, cell lines). Data were compared to expression in CD34+ hematopoietic cells. Based on the miR-142 expression, clinical data such as overall survival was analyzed. RESULTS: MiR-142 expression in all leukemia cell lines and 86 % of the de novo samples was higher than in CD34+ cells. This difference could be detected in both, myeloid and lymphoid neoplastic cells. In AML patients with intermediate cytogenetic risk a high miR-142 expression was associated with a better overall survival. CONCLUSIONS: MiR-142 expression in acute lymphoblastic as well as myeloid leukemia cells is higher than in CD34+ cells. Additionally, miR-142 expression might have prognostic relevance in AML-patients with otherwise an intermediate cytogenetic risk.
OBJECTIVES: The microRNA 142 (miR-142) is expressed at high levels in mature hematopoietic cells and has a crucial role during T-lymphocyte development. Its role in leukemogenesis is unclear. PATIENTS AND METHODS: Expression of miR-142 was analyzed in acute myeloid and lymphoblastic leukemia cells (de novo, cell lines). Data were compared to expression in CD34+ hematopoietic cells. Based on the miR-142 expression, clinical data such as overall survival was analyzed. RESULTS:MiR-142 expression in all leukemia cell lines and 86 % of the de novo samples was higher than in CD34+ cells. This difference could be detected in both, myeloid and lymphoid neoplastic cells. In AMLpatients with intermediate cytogenetic risk a high miR-142 expression was associated with a better overall survival. CONCLUSIONS:MiR-142 expression in acute lymphoblastic as well as myeloid leukemia cells is higher than in CD34+ cells. Additionally, miR-142 expression might have prognostic relevance in AML-patients with otherwise an intermediate cytogenetic risk.
Authors: Peter P Ruvolo; Vivian R Ruvolo; Rodrigo Jacamo; Jared K Burks; Zhihong Zeng; Seshagiri R Duvvuri; Liran Zhou; Yihua Qiu; Kevin R Coombes; Nianxiang Zhang; Suk Y Yoo; Rongqing Pan; Numsen Hail; Marina Konopleva; George Calin; Steven M Kornblau; Michael Andreeff Journal: Biochim Biophys Acta Date: 2014-05-21
Authors: Chen Meng; Oana A Zeleznik; Gerhard G Thallinger; Bernhard Kuster; Amin M Gholami; Aedín C Culhane Journal: Brief Bioinform Date: 2016-03-11 Impact factor: 11.622
Authors: Maria C Trissal; Terrence N Wong; Juo-Chin Yao; Rahul Ramaswamy; Iris Kuo; Jack Baty; Yaping Sun; Gloria Jih; Nishi Parikh; Melissa M Berrien-Elliott; Todd A Fehniger; Timothy J Ley; Ivan Maillard; Pavan R Reddy; Daniel C Link Journal: Cancer Res Date: 2018-05-03 Impact factor: 13.312